Background: We conducted a phase I trial of gemcitabine (gem) with concurrent radiotherapy in patients with muscleinvasive bladder cancer (BC) ineligible for surgery or cisplatin or refusing organ loss.
introduction Radical cystectomy has been the standard of care for muscleinvasive bladder cancer (BC) in the United States and in Europe. As an alternative, bladder preservation strategies have repeatedly been proposed with multimodality approaches, that include complete transurethral resection of the bladder (TUR-B) followed by radiation and chemotherapy as a radiosensitizer, for selected patients with limited tumor stages and those refusing or ineligible for major surgery.
Cisplatin alone or in combination has been the most frequently used radiosensitizer [1] . Radiation therapy alone as the definitive treatment of BC without a radiosensitizer provides insufficient local control [1, 2] .
Gemcitabine has a favorable toxicity profile and is well tolerated in cisplatin ineligible patients with moderately impaired renal function. It is a pyrimidine antimetabolite which inhibits cellular DNA synthesis and has single-agent activity against urothelial cancer in various clinical settings [3] .
In an in vitro investigation comparing the once weekly with a twice-weekly application of gemcitabine in combination with radiotherapy, a more intensive radiosensitizing effect for the twice-weekly schedule was found. In a consecutive experiment in mice, the twice-weekly schedule resulted in a higher therapeutic index [4] . Clinical application of gemcitabine as a radiosensitizer has to be implemented carefully because of an increased toxicity to normal tissues [5] .
Our aim was to establish the maximum-tolerated dose (MTD) and the dose recommended (RD) for further studies as well as the long-term toxicity of gemcitabine as a radiosensitizer in the treatment of BC in patients who are ineligible for cisplatin or inoperable for different reasons or who refuse cystectomy.
patients and methods patient eligibility
Eligible patients had histologically or cytologically confirmed muscleinvasive BC in clinical stages T2-4, N0-1 and M0. Inclusion criteria were inoperability due to tumor extent (locally advanced disease), evaluated by a multidisciplinary team or due to co-morbidity. Patients were also eligible when they refused surgery, or in case of a low performance status (PS) and/ or a high age >80 years which were the reasons for refusing surgery by the urologists. Further (selected) inclusion criteria were glomerular filtration rate (GFR) ≥30 ml/min (Cockcroft & Gault formula); PS 0-2 (WHO scale); before patient registration, written informed consent had to be given. The study was conducted in accordance with the International Conference on Harmonisation/Good Clinical Practice and the appropriate local regulatory requirement(s).
study end points, design and treatment
This trial was a two-center, phase I dose finding study to determine the MTD and the RD for further development with regard to acute toxicity of twice-weekly gemcitabine as a concurrent i.v. radiosensitizer together with definitive radiation therapy to the urinary bladder as the primary and late toxicity as the secondary end point.
Radiation was administered with single doses of 1.85 Gy (ICRU), 5 fractions/week with field shrinking technique based on individual 3D treatment planning (CT and/or MRI assisted) by isocentric multifield techniques, individual portal shaping, high energetic photons (15 MV) on linear accelerators. Treatment volumes comprised the total bladder plus perivesical area and iliac lymph nodes up 46.25 Gy, followed by a boost to bladder plus perivesical area to a total dose of 55.5 Gy. All procedures, planning, simulation and treatment were carried out with an empty bladder.
In this trial, dose-limiting toxicity (DLT) was defined as nonhematologic toxicity (except inadequately treated nausea, vomiting and alopecia) and/or hematologic toxicity grade ≥3, both necessitating a discontinuation or interruption of radiation and/or gemcitabine for >1 week. The late toxicities derived from irradiation were classified by RTOG/EORTC.
The first two patients per dose level were followed for 6 weeks for acute toxicity. In case of zero to one of two patients with DLT, further four patients were to be entered at that same dose level. In case of two DLTs in the first two patients of a dose level, or whenever two of six patients per dose-level experienced DLT, the level was to be closed immediately. Consequently, a new dose level, which had to be the mean of the last two ones was to be opened. The MTD was defined aiming at taking into consideration the composite nature of toxicity of chemoradiotherapy including acute and late toxicity.
The MTD was defined as follows: the dose level at which 2 or more of 6 patients experience acute DLT (which leads to discontinuation of RT and/or gem for >1 week) and at which more than 2 of 18 patients develop late toxicity; the RD for further phase II studies was to be the dose level at which less than 2 of 6 (≤17%) patients experience DLT and at which not more than 11% develop late toxicity. Toxicity was evaluated according to the Common Toxicity Criteria and the RTOG/EORTC score.
After three dose levels, the whole cohort was to be followed for late toxicity, i.e. at least for 6 months, before more patients were allowed to be entered in the study at a new dose level. If not more than 2 of 18 (11%) patients had signs of late toxicity within the defined 6 months follow-up period, the next dose level was allowed to be started and, therewith, a new cohort of patients. In case, three or more of 18 (17%) patients experienced late toxicity, a dose level below the lowest one, in which late toxicity was observed was to be opened or the study was to be closed due to MTD reached for late toxicity.
Patients were included in the trial only after TUR-B with maximal tumor debulking whenever feasible. After a maximum of 6 weeks after the last TUR-B patients were registered and assigned to a dose level of gemcitabine twice weekly administered by a 30-min infusion no later than 2 h before radiation. The planned treatment period was 6 weeks. An interval of 72 h between the 2 weekly gemcitabine applications had to be ensured. The dose levels originally foreseen were (mg//m 2 ) 20, 33, 50, 66, 88 and 117. Two study amendments were submitted: the first one was triggered by the publication of an unexpected DLT in a similar US study at 33 mg/m 2 gemcitabine twice weekly [6] which necessitated an additional dose level of 27 mg/m 2 . The second one, which led to the additional dose level of 30 mg/m 2 , was a subsequent consequence of this additional dose level. This allowed six more patients to be included for safety reasons before interim study stop for 6 months was carried out to evaluate late toxicity.
baseline and treatment assessments including toxicity and response evaluation. Pretreatment evaluation included CT of chest and abdomen, cystoscopy, urinalysis, PS, weight, blood count and chemistry as well as baseline adverse event (AE) assessment. Dose adjustments were based on clinical assessment for toxicity and blood count twice a week, taken immediately before administration of chemotherapy, and blood chemistry, urinalysis and GFR calculation carried out once a week. At the end of treatment (week 7), patients were assessed with physical examination, blood chemistry, blood count and final cystoscopy including re-TURB, if necessary. Thereafter, patients were followed every 2 weeks for a total of 6 weeks. Further on follow-up visits were scheduled every 3 months for a minimum of 2 years after end of treatment.
dose adjustment and dose modification. Gemcitabine was held for WBC <2.0 × 10 9 /l, ANC <1.0 × 10 9 /l or platelets <50 × 10 9 /l or a GFR <30 ml/min until recovery to a GFR of ≥30 ml/ min, any grade 3/4 nonhematological toxicity until recovery to grade ≤2.
Resting of chemotherapy while continuing radiation treatment: if a toxicity other than hematological occurred, e.g. liver or renal toxicity or oral mucositis, radiotherapy should be continued while gemcitabine was deferred until this toxicity had recovered to grade ≤2.
Whenever radiotherapy had to be interrupted, chemotherapy was stopped until the restart of radiation.
Resting of radiation therapy: if grade 3 or 4 hematological or nonhematological toxicities were observed, radiation was discontinued until grade ≤2 was reached. Table 1 .
acute toxicities
For the evaluation of acute toxicity, only those AEs with possible, probable and definite relation to treatment were taken in account (Table 2) . Overall, no grade 4 toxicities were observed. No DLTs were observed in dose levels 1-4 (20, 27, 30, 33 mg/m 2 ). The MTD was defined at dose level 5 (50 mg/m 2 gemcitabine twice a week) with G3 liver enzyme elevation (alanine aminotransferase, ALT) and G3 fatigue in one patient each. At the additional dose level of 40 mg/m 2 (according to the protocol extrapolated to be between the previous two levels), G3 fatigue and diarrhea (both DLTs) occurred in only one of six patients. Therefore, dose level 6 with 40 mg/m 2 gemcitabine twice a week became the provisional RD in this trial based on the evaluation of all acute toxicities.
late toxicity
A total of 33 (94%) patients were followed for ≥3 months and 22 (63%) patients were followed for ≥2 years. Our definition of overall late toxicity was AEs reported ≥3 months after termination of radiotherapy that was definitely, probably or possibly related to treatment at all dose levels. No grade 3 and 4 late toxicities were reported. Overall, the treatment was well tolerated. Most side-effects started during the active treatment phase and resolved within 1-2 months after radiation had been completed. Nineteen grade 1 or 2 AEs corresponded to our definition of late toxicity: fatigue (3), taste alteration (2), general weakness (1), edema (1), vertigo (1), lower abdominal pain (1), urinary frequency (3), discharge of mucus on stool (2), flatulence (1), proctitis (1), anorexia (1), axonal neuropathy (1), liver enzyme elevation (ALT) (1). response All 35 patients assessable for acute toxicity were also assessable for response at week 7. At that time point, 33 of 35 patients (94%) had no evidence of disease (NED), 1 patient had persistent tumor and, in one other patient, distant metastases were diagnosed.
The stage-related treatment efficacy at the 2-year follow-up, which was no primary goal of the trial, is summarized in Table 3 . The death of 20 patients was due to disease progression (6 patients) and noncancer-related comorbidities (5 patients) and, in 9 patients, the reason remained unknown (no secured information or autopsy).
discussion
The aim of this phase I study, to define the MTD and the RD for the further development of gemcitabine as a radiosensitizer, scheduled twice a week in a negatively selected group of BC patients that is frequently seen in daily clinical practice, has been reached. The MTD in our patient population was found to be 50 mg/m 2 and we defined the RD of gemcitabine twice a week plus radiation of the bladder with 55.5 Gy to be 40 mg/m 2 . Overall, in our trial, gemcitabine was well tolerated. ALT elevation grade 3, fatigue and diarrhea, were the DLTs confirming the toxicity pattern found in a previously published study of Kent et al. [6] . In several other BC phase I or II trials, gemcitabine once a week as a radiosensitizer was used without major liver toxicity [7] [8] [9] . Interestingly, biweekly gemcitabine and concomitant radiation did not cause liver toxicities in several other phase I/II trials, albeit in other tumor entities [10] .
The reason for the liver enzyme elevation that turned out unexpectedly to get dose-limiting in our study as in the one by Kent et al. has not been definitely elucidated. Transient mild abnormalities of liver function tests under gemcitabine are very common (70%) [11] . They are not increasing with treatment duration, schedule or cumulative dose. Therefore, it is remarkable that only in two more out of a plethora of studies in various tumor entities such as non-small-cell lung cancer, head-andneck or pancreatic cancer [10] testing gemcitabine as radiosensitizer G3 liver function test abnormalities have been reported, both in pancreatic cancer [12, 13] . In the prospectively randomized study of Loehrer et al. which compared weekly gemcitabine 600 mg/m 2 combined with irradiation versus gemcitabine 1000 mg/m 2 weekly without irradiation [12] , G3 ALT increase was reported in 3% each. In another prospectively randomized phase II trial, Van Laethem compared gemcitabine 1000 mg/m 2 weekly plus irradiation with gemcitabine 1000 mg/m 2 without irradiation and reported on 12% G3 elevation of ALT [13] . In no other phase I trial, besides ours and the one of Kent et al. [6] , hepatotoxicity was dose-limiting. It is a matter of speculation Dose level 1 (20 mg/m 2 ), n = 6 2 (27 mg/m 2 ), n = 6 3 (30 mg/m 2 ), n = 6 4 (33 mg/m 2 ), n = 6 5 (50 mg/m 2 ), n = 5 6 (40 mg/m 2 ), n = 6 All (%), N = 35 (100%) Grade G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4
Hematologic whether the scheduling twice weekly has added to the impairment of the liver function observed in the two phase I trials mentioned. Unlike in the trial of Kent et al., where 33 and 27 mg/m 2 gemcitabine twice weekly were reported as MTD and RD, respectively, we used 55.5 Gy total radiation dose, which was slightly lower than in the Kent trial but comparable with others [2]. A comparison between these two regimens (i.e. 60 Gy plus 27 mg/m 2 versus 55.5 Gy plus 40 mg/m 2 gemcitabine, both twice weekly) has its inherent limitations; on the one hand, there is the higher median age (75 years in our trial versus 62 years in the trial by Kent) [6] ; on the other hand, there were more patients with advanced tumor stage in our trial (Table 3 ) [6] . Besides, ineligibility for cisplatin and inoperability of the primary tumor were major reasons for refusal of surgery and thus an indication for a frailer and more advanced patient population. Whether the higher gemcitabine dose of our trial can compensate for the lower radiation dose, when compared with the trial of Kent [6] , is at best speculative. Additional BC phase I and II trials exploring different gemcitabine and radiotherapy doses and schedules are summarized in Table 4 . Of note, Choudhury et al. [8] published a phase II study using weekly gemcitabine 100 mg/m 2 and 52.5 Gy radiation over 4 weeks and showed promising results with a 64% local control rate (bladder in place) and very low long-term toxicity.
The specific claim of radiosensitization in comparison with conventional radiotherapy is the selective sensitization of tumor compared with normal tissue. In our study, we have approached this goal by achieving an acceptable tumor control rate in mostly locally advanced and elderly patients and a 40% bladderintact survival with a well-tolerated treatment regimen and no G3 late toxicities at the 2-year follow-up. The same is true for the long-term toxicity observations by Oh et al. [14] in a prognostically much better group of BC patients. In another study [2], the 2-year recurrence-free rate was reported to be 67% in the chemoradiotherapy group.
To date, chemoradiation in BC, compared with radiation alone, has been shown to improve only the locoregional recurrence rate but not overall survival [1, 2] . Therefore, the legitimate rationale also with our 'low-dose-twice a week' gemcitabine regimen was local control.
Late toxicity after radiation therapy of the urinary bladder has been a concern. Yet, it is infrequent, accounting for 0.5%-20% of patients, mostly low grade and depending on the radiation dose, technique and the number of previous TUR-B procedures [15] . This analysis provides data of a median of 32 months follow-up. So far, we did not observe long-term toxicities grades 3-4.
In our phase I trial, gemcitabine 40 mg/m 2 , twice a week, with 55.5 Gy radiation to the urinary bladder was determined to be the recommended dose in this patient population. 
